PLAU, transcriptionally negatively regulated by GATA6, promotes lung squamous carcinoma cell proliferation and migration
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Plasminogen activator urokinase (PLAU) drives lung squamous cell carcinoma (LUSC) progression and is overexpressed in tumors. GATA-binding factor 6 (GATA6) transcriptionally inhibits PLAU, offering a potential therapeutic target for LUSC.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Lung squamous cell carcinoma (LUSC) presents a significant mortality challenge with limited treatment options.
- Plasminogen activator urokinase (PLAU) is implicated in tumor malignancy, but its specific role in LUSC progression is unclear.
- GATA-binding factor 6 (GATA6) regulates lung development and inhibits LUSC cell growth, yet its regulatory mechanisms, particularly concerning PLAU, require further investigation.
Purpose Of The Study
- To elucidate the oncogenic role of PLAU in LUSC development and progression.
- To investigate the transcriptional regulatory mechanism of GATA6 on PLAU expression in LUSC.
- To identify potential therapeutic targets within the GATA6/PLAU pathway for LUSC treatment.
Main Methods
- Differential gene expression analysis (GEO datasets, RNA-seq) and Venn analysis identified potential GATA6 targets.
- Real-time PCR, immunoblotting, and dual-luciferase reporter assays confirmed GATA6's transcriptional regulation of PLAU.
- Cell proliferation (EdU), 3D culture, migration (Transwell), and immunohistochemistry assays assessed PLAU's function and expression in LUSC tissues.
Main Results
- PLAU overexpression significantly enhanced LUSC cell proliferation and migration.
- PLAU was found to be overexpressed in LUSC tissues compared to normal tissues.
- High PLAU expression independently predicted poor prognosis in LUSC patients and is transcriptionally regulated by GATA6.
Conclusions
- PLAU acts as a novel oncogene in LUSC, promoting tumor progression.
- A new molecular mechanism involving GATA6's transcriptional inhibition of PLAU in LUSC was identified.
- Targeting the GATA6/PLAU pathway presents a promising strategy for developing novel LUSC therapeutics.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Three of the best-understood negative regulators are p53, p21, and retinoblastoma protein (Rb). The regulatory roles of each of these proteins were discovered after faulty copies were found in cells with uncontrolled replication (i.e.,...
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Guanine nucleotide exchange factors or GEF,
GTPase-activating proteins or GAPs, and
Guanine nucleotide-dissociation inhibitors or GDIs.
The GEF activates the GTPase by exchanging the bound-GDP with GTP. The...
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...